In Danish postmenopausal women, the

Ile568Asn loss-of-function polymorphism was associated Rabusertib with 10-year vertebral fracture incidence and increased rate of bone loss [16]. In contrast, we, like two other Everolimus ic50 association studies [17, 20], did not find any association between the Ile568Asn loss-of-function polymorphism and BMD. However, only two women homozygous for the variant allele could be identified in this study. Since both the Arg307Gln and Ile568Asn were previously showed to be associated with either decreased BMD and/or fracture risk, the observed low prevalence of these SNPs in our fracture cohort is contrary to our expectations. The variant allele of the Gly150Arg polymorphism in our study was associated with decreased lumbar spine BMD, supporting the results found by Husted and colleagues [17], who observed reduced total hip BMD values in subjects carrying the 150Arg allele. This effect on BMD might be explained by its complete loss-of-function effect on the P2X7R [25, 32]. In line with several in vitro studies which showed that the variant allele of the Glu496Ala polymorphism was associated with a loss of receptor function [16, 23, 28, 33, 34], human cohort studies showed this polymorphism to be associated with decreased BMD values in both men and women [17] and increased fracture incidence over 10 years after menopause [16]. In concordance with these findings, we also found significantly decreased

BMD values at the total hip in women with at least one variant allele of the

Glu496Ala Enzalutamide nmr polymorphism. Furthermore, analysis of haplotypes containing the Glu496Ala polymorphism (i.e. haplotype P2X7-3) also showed a significant association with decreased BMD values at the lumbar spine. This is in line with the results found by Stokes et al. [24], indicating that this haplotype is associated with decreased receptor function. The diglyceride studied P2X7R SNPs mostly affect the lumbar spine. Since bone turnover is primarily taking place on the bone surfaces and the changes in BMD due to the P2X7R SNPs are relatively small, one possible explanation for affecting this particular skeletal site could be that trabecular bone is lost more rapidly than cortical bone. As the amount of trabecular bone is higher in the vertebrae than in the hip, the bone loss will be most pronounced in the vertebral spine. The present study has several limitations. First, our study population is not population-based, as the recruitment strategy was based on the presence of a fracture. The prevalence of low BMD is, therefore, expected to be higher in our study population than in the general population. Furthermore, if the studied P2 receptor SNPs could affect fracture risk either directly or indirectly (independent of BMD) then the prevalence of this particular SNP would also be expected to be higher in our study sample than in the general population. This could potentially lead to bias in the results in the sense that extrapolation to the general population is compromised.